Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244959 · ClinicalTrials.gov registry record · Phase 2
Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT00244959 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 54 participants.
The verdict
NCT00244959, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole may fight breast cancer by lowering the amount of estrogen the body makes. PURPOSE: This phase II trial is studying how anastrozole effects postmenopausal women who have undergone surgery for ductal carcinoma in situ or stage I, stage II, or stage III breast cancer.
Interventions
- DRUG anastrozole
- PROCEDURE adjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2004-01 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244959
The ClinicalTrials.gov registry entry for NCT00244959 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which anastrozole is the first listed.
NCT00244959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00244959 about?
NCT00244959 is a clinical study titled "Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer". RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole may fight breast cancer by lowering the amount of estrogen the body makes. PURPOSE: This phase II trial is studying how anastrozole effects postmenopausal women who have undergone surgery for ductal c...
What is the current status of trial NCT00244959?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2004-01. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00244959?
The interventions under investigation include: anastrozole (DRUG), adjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00244959?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.